The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer

Cancer Letters

Volumn 248, Issue 1, 2007, Pages 153-163

  Fu, Jianjiang ^a   Ding, Yan ^a   Huang, Dan ^a   Li, Hongyan ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Angiogenesis; LGD1069; Retinoid X receptor; VEGF

Indexed keywords

BEXAROTENE; MITOGEN ACTIVATED PROTEIN KINASE; RETINOID X RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER MODEL; CAPILLARY DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; HOLLOW FIBER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, CD31; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; RETINOID X RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAHYDRONAPHTHALENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33847325833     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.06.012     Document Type: Article

References (30)

1. Mousa S.A. Mechanisms of angiogenesis: potential therapeutic targets. In: Mousa S.A. (Ed). Agioggenesis Inhibitors and Stimulators Potential Therapeutic Implications (2000), Eurekah.com/Landes Bioscience, Georgetown, Texas 1-12
2. McColl B.K., Stacker S.A., and Achen M.G. Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS 112 (2004) 463-480
3. Zachary I. Signal transduction in angiogenesis. EXS 94 (2005) 267-300
4. Holmes D.I., and Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 6 (2005) 209
5. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10 (1996) 940-954
6. Chen J.Y., Clifford J., Zusi C., Starrett J., Tortolani D., Ostrowski J., Reczek P.R., Chambon P., and Gronemeyer H. Two distinct actions of retinoid-receptor ligands. Nature 382 (1996) 819-822
7. Mangelsdorf D.J., and Evans R.M. The RXR heterodimers and orphan receptors. Cell 83 (1995) 841-850
8. Khuri F.R., Lotan R., Kemp B.L., Lippman S.M., Wu H., Feng L., Lee J.J., Cooksley C.S., Parr B., Chang E., Walsh G.L., Lee J.S., Hong W.K., and Xu X.C. Retinoic acid receptor -β as a prognostic indicator in stage I non-small-cell lung cancer. J. Clin. Oncol. 18 (2000) 2798-2804
9. Widschwendter M., Berger J., Hermann M., Muller H.M., Amberger A., Zeschnigk M., Widschwendter A., Abendstein B., Zeimet A.G., Daxenbichler G., and Marth C. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J. Natl. Cancer Inst. 92 (2000) 826-832
10. Lin X.F., Zhao B.X., Chen H.Z., Ye X.F., Yang C.Y., Zhou H.Y., Zhang M.Q., Lin S.C., and Wu Q. RXRalpha acts as a carrier for TR3 nuclear export in a 9-cis retinoic acid-dependent manner in gastric cancer cells. J. Cell Sci. 117 (2004) 5609-5621
11. Mulshine J.L. Chemoprevention of head and neck cancer. Clin. Adv. Hematol. Oncol. 3 (2005) 763-765
12. Boehm M.F., Zhang L., Badea B.A., White S.K., Mais D.E., Berger E., Suto CM., Goldman M.E., and Heyman R.A. Synthesis and structureactivity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 37 (1994) 2930-2941
13. Henney J.E. From the food and drug administration. JAMA 283 (2000) 1131
14. Yen W.C., and Lamph W.W. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol. Cancer Ther. 4 (2005) 824-834
15. Yen W.C., Corpuz M.R., Prudente R.Y., Cooke T.A., Bissonnette R.P., Negro-Vilar A., and Lamph W.W. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin. Cancer Res. 10 (2004) 8656-8664
16. Yen W.C., and Lamph W.W. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate 9999 (2005) 1-12
17. Pages G., and Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene - a concert of activating factors. Cardiovasc. Res. 65 (2005) 564-573
18. Yen W.C., Prudente R.Y., Corpuz M.R., Negro-Vilar A., and Lamph W.W. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br. J. Cancer. 94 (2006) 654-660
19. Hollingshead M.G., Alley M.C., Camalier R.F., Abbott B.J., Mayo J.G., Malspeis L., and Grever M.R. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57 (1995) 131-141
20. Hasan J., Shnyder S.D., Bibby M., Double J.A., Bicknel R., and Jayson G.C. Quantitative angiogenesis assays in vivo - a review. Angiogenesis 7 (2004) 1-16
21. Phillips M.R., and Bibby M.C. Hollow fiber assay for tumor angiogenesis. In: Murray J.C. (Ed). Angiogenesis Protocols (2001), Humana Press Inc., Totowa, NJ 87-93
22. Fox S.B. Microscopic assessment of angiogenesisin tumors. In: Murray J.C. (Ed). Angiogenesis Protocols (2001), Humana Press Inc., Totowa, NJ 29-46
23. Xie K., Wei D., Shi Q., and Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor 15 (2004) 297-324
24. Javelaud D., and Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-b: implications for carcinogenesis. Oncogene 24 (2005) 5742-5750
25. Hunter T. Protein kinases and phosphatases: the Yin and Yang of protein phosphorylation and signaling. Cell 80 (1995) 225-236
26. Lee H.Y., Sueoka N., Hong W.K., Mangelsdorf D.J., Claret F.X., and Kurie J.M. All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Mol. Cell. Biol. 19 (1999) 1973-1980
27. Xu Q., Konta T., Furusu A., Nakayama K., Lucio-Cazana J., Fine L.G., and Kitamura M. Transcriptional induction of mitogen-activated protein kinase phosphatase 1 by retinoids. Selective roles of nuclear receptors and contribution to the antiapoptotic effect. J. Biol. Chem. 277 (2002) 41693-41700
28. Jassem J., Zatloukal P., Ramlau R., Schwarzenberger P., Orlov S., Rodrigues-Pereira J., Temperley G., Mabry M., Negro-Vilar A., Dziewanowska Z., and SPIRIT I Lung Cancer Study Group. A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) 23 (2005) 7024
29. Wang Y., Zhang Z., Yao R., Jia D., Wang D., Lubet R.A., and You M. Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 25 (2006) 1320-1329
30. Pereira M.A., Kramer P.M., Nines R., Liu Y., Alyaqoub F.S., Gunning W.T., Steele V.E., and Lubet R.A. Prevention of mouse lung tumors bytargretin. Int. J. Cancer. 118 (2006) 2359-2362